Category: Oncotarget

Oncotarget News

Crossroads: The Role of Biomarkers in the Management of Lumps in the Breast

May 2, 2023

A biomarker or set of biomarkers to inform on the individual progression risk would be beneficial to the patient and cost-effective for the healthcare system.”BUFFALO, NY- May 2, 2023 –... read more

Figure 3: Cytokine expression and cell viability upon mRNA silencing of STAT3 isoforms

Oncotarget

Differential Silencing of STAT3 Isoforms Leads to Changes in STAT3 Activation

April 26, 2023

Our study emphasizes the importance of distinguishing between STAT3α and STAT3β proteins and their active forms when discussing STAT3-related cancer diagnosis and therapy.”BUFFALO, NY- April 26, 2023 – A new... read more

Figure 1: Tumor necroptosis promotes metastasis of breast cancer by suppressing anti-tumor immunity.

Oncotarget

Tumor Necroptosis Promotes Metastasis by Modulating Tumor-Host Immunity

April 25, 2023

we found that blocking necroptosis leads to the inhibition of metastasis in mouse breast cancer models [...]”BUFFALO, NY- April 24, 2023 – A new editorial paper was published in Oncotarget's Volume... read more

Figure 2: Kaplan-Meier survival curve of duodenal adenocarcinoma patients with elevated CA 19-9 (green) and with normal CEA (blue).

Oncotarget

CA 19-9 and CEA in Prognosis of Duodenal Adenocarcinoma: A Retrospective Study

April 18, 2023

To our knowledge, there are no studies evaluating the prognostic importance of CEA and Ca 19-9 in patients with DA [duodenal adenocarcinoma].”BUFFALO, NY- April 18, 2023 – A new research... read more

Figure 2: Rapamycin prevents cancer by slowing tumor progression (hypothetical schema).

Oncotarget

Cancer Prevention With Rapamycin

April 17, 2023

long-term treatment with rapamycin slows down aging, a major risk factor for cancer [...]”BUFFALO, NY- April 17, 2023 – A new research perspective was published in Oncotarget's Volume 14 on April... read more

Figure 1: Pre- and post-treatment scans confirmed partial responder. (From a phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850.”)

Oncotarget

Riluzole and Sorafenib in Patients With Advanced Solid Tumors: A Phase I Trial

April 12, 2023

Our phase I study determined the tolerable dose of this combination and investigated its biologic effects.” BUFFALO, NY- April 12, 2023 – A new research paper was published in Oncotarget's... read more

Figure 2: Active pharmacological intervention trials in TNBC.

Oncotarget

Crosstalk Between Triple Negative Breast Cancer and Microenvironment

April 10, 2023

the study of immunotherapy for treating triple negative breast cancer might still be at its early stages of development but is full of future promise.” BUFFALO, NY- April 10,... read more

Oncotarget

Cancer-Associated Fibroblasts: Challenges and Opportunities

April 5, 2023

Beyond detection of cancer, CAFs are being actively pursued as targets for therapy.” BUFFALO, NY- April 5, 2023 – A new editorial perspective was published in Oncotarget's Volume 14 on... read more

Figure 1: The molecular mechanism(s) of how Wnt5a signaling could (i) induce ROR1 and cortactin association, tyrosine phosphorylation of cortactin, and activation of RhoA, (ii) enhance F-actin polymerization, and (iii) subsequently promote migration or metastasis of cancer cells.

Oncotarget

Impact of Cortactin in Cancer Progression

April 4, 2023

Cortactin (also known as EMS1 or CTTN) is expressed broadly in a variety of cancers [...]” BUFFALO, NY- April 4, 2023 – A new editorial paper was published in Oncotarget's Volume... read more

Oncotarget

Oncotarget at AACR Annual Meeting 2023

April 4, 2023

Impact Journals (Oncotarget's publisher) is proud to participate at the American Association for Cancer Research (AACR) Annual Meeting 2023, which convenes April 14-19 in Orlando, Florida.BUFFALO, NY-April... read more